Fully independent, financially sound
Selcia is fully independent and profitable. Since a management buyout in 2005 we have doubled our turnover and nearly tripled the number of employees.
A unique service offer
Selcia's integrated range of drug discovery services, together with 14C custom radiolabelling, is a unique offer amongst global life science CROs.
Exemplary scientific credentials
Two-thirds of our 70-strong scientific team have PhDs and have authored / co-authored over 450 papers and have been inventors on patents over 300 times. The extensive and varied industrial experience of our scientific staff enables us to offer a level of scientific creativity seldom found within a contract research organisation.
Overseas customers account for 75 per cent of our revenue. This figure continues to grow as we develop our service offer in Europe, the Americas, and the Far East.
A growing portfolio of drug development collaborations
We have drug development collaborations with a number of pharma and biotech partners across a range of therapeutic areas. This portfolio is set for further growth as we expand our drug discovery activities.
Modern GMP/GLP laboratory facilities
We have over 3,000 m2 of modern laboratory space at our R+D facilities in Ongar (UK). Our GLP certified analytical laboratory is fully equipped with state-of-the-art instrumentation. Selcia also holds a GMP certificate for the preparation of 14C labelled APIs.
A focus on natural products
Selcia has a particular focus and proven track record delivering novel clinical candidate drugs derived from natural products.
Strong In-house IP
Selcia has built a strong IP position for novel compound families directed at anti-infectives, anti-virals, inflammation, oncology and mitochondrial dysfunction. We are actively seeking collaborative programmes in these therapeutic areas.
An ethical approach to business
While we believe in openness, communication and transparency with our customers, we also have processes in place to ensure total confidentiality covers all compound and data deliverables and to prevent project cross contamination in-house.